Trials / Completed
CompletedNCT00150566
Efficacy and Safety of Lanthanum in Controlling Serum Phosphate Levels in Subjects With End Stage Renal Disease Who Require Treatment for High Levels of Phosphate in Their Blood
A Phase IIIb, Multi-center, Two-Cohort, Randomized Study, With an Open-Label Run-In and a Long-Term Extensions Phase, Assessing an Extended Dose Range of Lanthanum Carbonate in End Stage Renal Disease Subjects Receiving Hemodialysis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 460 (planned)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test how well higher doses of lanthanum carbonate reduce the pre-dialysis level of serum phosphorus in subjects undergoing dialysis due to end stage renal disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lanthanum carbonate |
Timeline
- Start date
- 2004-02-09
- Primary completion
- 2005-10-08
- Completion
- 2005-10-08
- First posted
- 2005-09-08
- Last updated
- 2021-06-08
Source: ClinicalTrials.gov record NCT00150566. Inclusion in this directory is not an endorsement.